Ibrutinib was approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) and in February 2014 for the treatment of chronic lymphocytic leukemia (CLL). This drug is now marketed in the U.S. under the brand name, Imbruvica.
This breakthrough drug is providing hope for patients who suffer from these debilitating forms of cancer. As reported by the Lymphoma Research Foundation, leading up to the approval of ibrutinib, a clinical study followed 85 patients with relapsed CLL, with an average of three previous treatments for each patient. The overall response rate to treatment was 71 percent, and two patients achieved a complete response. Response to treatment also proved to be long-lasting; an estimated 75 percent of patients reached 26 months of progression-free survival.
PCYC stock has been a top performer since Bob Duggan took over the company in 2008, increasing several thousand percent during that time.